June 2nd 2017, 11:47pm
A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.
June 2nd 2017, 11:07pm
Progression-free survival was improved for postmenopausal women with HER2-negative advanced breast cancer when treated with Kisqali plus letrozole.
March 15th 2017, 9:19pm
Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.
March 15th 2017, 8:20pm
Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.
March 15th 2017, 6:41pm
Jubilee Brown, M.D., obstetrician-gynecologist, Levine Cancer Institute, Carolinas HealthCare System, discusses genetic counseling for patients with breast and ovarian cancer.
March 15th 2017, 4:52pm
PARP inhibitors like niraparib are bringing big change to the treatment of ovarian cancer, says Kathleen N. Moore, M.D.
March 15th 2017, 12:37am
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
March 14th 2017, 10:32pm
The PARP inhibitor niraparib proved to be effective in improving progression-free survival in recurrent ovarian cancer, according to a recent study.
March 13th 2017, 11:53pm
Concern about vaccine safety and perceived lack of necessity remain the main reasons parents give for not having their teenage daughter vaccinated against HPV.
March 13th 2017, 10:26pm
Jubilee Brown, M.D., answers some common questions about genetic counseling in patients with ovarian cancer.
March 13th 2017, 9:31pm
Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
March 13th 2017, 8:59pm
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
March 13th 2017, 1:12am
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.